Skip to main content

Advertisement

SpringerLink
Log in

Novel kinase inhibitors in renal cell carcinoma: Progressive development of static agents

  • Published:
Current Urology Reports Aims and scope Submit manuscript

Abstract

The rapidly expanding knowledge regarding neoplastic diseases is providing a plethora of new targets for drug discovery and development as exemplified by recent data in renal cell carcinoma. The initial experience with molecularly “targeted” agents has demonstrated that development of the newer non-cytotoxic agents will provide unique challenges requiring modification of many traditional drug development concepts and methods. We discuss recently reported data from a few renal cell carcinoma trials with putative cytostatic agents and highlight issues that need to be addressed for efficient development of cytostatic agents during various phases of clinical development.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Jemal A, Tiwari RC, Murray T, et al.: Cancer statistics, 2004. CA Cancer J Clin 2004, 54:8–29.

    Article  PubMed  Google Scholar 

  2. Reuter VE, Presti JC Jr: Contemporary approach to the classification of renal epithelial tumors. Semin Oncol 2000, 27:124–137.

    PubMed  CAS  Google Scholar 

  3. Beck SD, Patel MI, Snyder ME, et al.: Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma. Ann Surg Oncol 2004, 11:71–77.

    Article  PubMed  Google Scholar 

  4. Motzer RJ, Russo P: Systemic therapy for renal cell carcinoma. J Urol 2000, 163:408–417.

    Article  PubMed  CAS  Google Scholar 

  5. Stadler WM, Huo D, George C, et al.: Prognostic factors for survival with gemcitabine plus 5-fluorouracil based regimens for metastatic renal cancer. J Urol 2003, 170:1141–1145.

    Article  PubMed  CAS  Google Scholar 

  6. Stadler WM, Halabi S, Ernstoff MS, et al.: A phase II study of gemcitabine (G) and capecitabine (C) in patients with metastatic renal cell cancer (mRCC): a report of Cancer and Leukemia Group B #90008 [abstract]. J Clin Oncol 2004, ASCO Annual Meeting Proceedings Post-Meeting Edition 22 (15 Suppl):4515.

  7. Yang JC, Sherry RM, Steinberg SM, et al.: Randomized study of high dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 2003, 21:3127–3132.

    Article  PubMed  CAS  Google Scholar 

  8. Coppin C, Porzsolt F, Kumpf J, et al.: Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2000:CD001425.

  9. Vogelzang NJ, Stadler WM: Kidney cancer [see comments]. Lancet 1998, 352:1691–1696.

    Article  PubMed  CAS  Google Scholar 

  10. Dinney CP, Bielenberg DR, Perrotte P, et al.: Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-alpha administration. Cancer Res 1998, 58:808–814.

    PubMed  CAS  Google Scholar 

  11. Maynard MA, Ohh M: von Hippel-Lindau tumor suppressor protein and hypoxia-inducible factor in kidney cancer. Am J Nephrol 2004, 24:1–13. An excellent review focused on the current molecular understanding of the roles of HIF and pVHL in the development of VHL-associated clear-cell renal cell carcinoma.

    Article  PubMed  CAS  Google Scholar 

  12. Kaelin WG Jr.: The von Hippel-Lindau tumor suppressor gene and kidney cancer. Clin Cancer Res 2004, 10:6290S-6295S. This review focused on the role of von Hippel-Lindau gene in kidney cancer also discusses and speculates on the clinical relevance of the current knowledge.

    Article  PubMed  CAS  Google Scholar 

  13. Herman JG, Latif F, Weng Y, et al.: Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci U S A 1994, 91:9700–9704.

    Article  PubMed  CAS  Google Scholar 

  14. Gnarra JR, Tory K, Weng Y, et al.: Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 1994, 7:85–90.

    Article  PubMed  CAS  Google Scholar 

  15. Gnarra JR, Duan DR, Weng Y, et al.: Molecular cloning of the von Hippel-Lindau tumor suppressor gene and its role in renal carcinoma. Biochim Biophys Acta 1996, 1242:201–210.

    Google Scholar 

  16. Iliopoulos O, Levy AP, Jiang C, et al.: Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci U S A 1996, 93:10595–10599.

    Article  Google Scholar 

  17. Maxwell PH, Wiesener MS, Chang GW, et al.: The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999, 399:271–275.

    Article  PubMed  CAS  Google Scholar 

  18. Turner KJ, Moore JW, Jones A, et al.: Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation. Cancer Res 2002, 62:2957–2961.

    PubMed  CAS  Google Scholar 

  19. Wang YQ, Luk JM, Ikeda K, et al.: Regulatory role of vHL/HIF-1a in hypoxia-induced VEGF production in hepatic stellate cells. Biochem Biophys Res Commun 2004, 317:358–362.

    Article  PubMed  CAS  Google Scholar 

  20. Wykoff CC, Beasley NJ, Watson PH, et al.: Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res 2000, 60:7075–7083.

    PubMed  CAS  Google Scholar 

  21. Presta LG, Chen H, O’Connor SJ, et al.: Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997, 57:4593–4599.

    PubMed  CAS  Google Scholar 

  22. Gordon MS, Margolin K, Talpaz M, et al.: Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001, 19:843–850.

    PubMed  CAS  Google Scholar 

  23. Yang JC, Haworth L, Sherry RM, et al.: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003, 349:427–434. One of the first published articles using an “antiangiogenic” therapy and suggesting a clinical benefit in patients with renal cancer. The article also illustrates the importance of utilizing randomized clinical trial designs for phase II oncology trials to address challenges facing investigators in development of cytostatic agents.

    Article  PubMed  CAS  Google Scholar 

  24. Rini BI, Halabi S, Taylor J, et al.: Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon or interferon plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma. Clin Cancer Res 2004, 10:2584–2586.

    Article  PubMed  CAS  Google Scholar 

  25. Wilhelm S, Carter C, Tang LY, et al.: BAY 43-9006 exhibits broad spectrum anti-tumor activity and targets Raf/MEK/ERK pathway and receptor tyrosine kinases involved in tumour progression and angiogenesis [abstract]. Presented at the International Conference on Molecular Targets and Cancer Therapeutics, AACR-NCI-EORTC Proc 2003; A78.

  26. Strumberg D, Voliotis D, Moeller JG, et al.: Results of phase I pharmacokinetic and pharmacodynamic studies of the Raf kinase inhibitor BAY 43-9006 in patients with solid tumours. Int J Clin Pharmacol Ther 2002, 40:580–581.

    PubMed  CAS  Google Scholar 

  27. Rosner GL, Stadler WM, Ratain MJ: Randomized discontinuation design: application to cytostatic antineoplastic agents. J Clin Oncol 2002, 22:4478–4484. This article discusses the use of a randomized discontinuation design in the context of cytostatic anticancer drug development with one example of such a study.

    Article  Google Scholar 

  28. Ratain MJ, Flaherty KT, Stadler WM, et al.: Preliminary antitumor activity of BAY 43-9006 in metastatic renal cell carcinoma and other advanced refractory solid tumors in a phase II randomized discontinuation trial [abstract]. J Clin Oncol 2004, 22:382 (abst 4501).

    Article  Google Scholar 

  29. Bayer and Onyx corporation press release. Accessible at http://biz.yahoo.com/prnews/041025/nym036 1.html

  30. Therasse P, Arbuck SG, Eisenhauer EA, et al.: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cnacer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205–216.

    Article  PubMed  CAS  Google Scholar 

  31. Rosen L, Mulay M, Long J, et al.: Phase I trial of SU011248, a novel tyrosine kinase inhibitor in advanced solid tumors [abstract]. Proc ASCO 2003, 22:765.

    Google Scholar 

  32. Mendel DB, Laird AD, Xin X, et al.: In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003, 9:327–337.

    PubMed  CAS  Google Scholar 

  33. Motzer RJ, Rini BI, Michaelson MD, et al.: SU011248, a novel tyrosine kinase inhibitor, shows antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma: results of a phase 2 trial [abstract]. J Clin Oncol 2004, 22:3820.

    Article  Google Scholar 

  34. Salomon DS, Brandt R, Ciardiello F, et al.: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Haem, 1995, 19:183–232.

    Article  CAS  Google Scholar 

  35. Grandis JR, Sok JC: Signaling through the epidermal growth factor receptor during the development of malignancy. Pharmacol Ther 2004, 102:37–46.

    Article  PubMed  CAS  Google Scholar 

  36. Yoshida K, Tosaka A, Takeuchi S, et al.: Epidermal growth factor receptor content in human renal cell carcinomas. Cancer 1994, 73:1913–1918.

    Article  PubMed  CAS  Google Scholar 

  37. Drucker B, Bacik J, Ginsberg M, et al.: Phase II trial of ZD1839 in patients with advanced renal cell carcinoma. Invest New Drugs 2003, 21:341–345.

    Article  PubMed  CAS  Google Scholar 

  38. Motzer R, Amato R, Todd M, et al.: Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma. Invest New Drugs 2003, 21:99–101.

    Article  PubMed  CAS  Google Scholar 

  39. Hainsworth JD, Sosman JA, Spigel DR, et al.: Phase II trial of bevacizumab and erlotinib in patients with metastatic renal carcinoma (RCC) [abstract]. J Clin Oncol 2004, 22:382.

    Google Scholar 

  40. Herbst RS, Prager D, Hermann R, et al.: TRIBUTE - A phase III trial of erlotinib HCl (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol 2004, 22:7011.

    Article  CAS  Google Scholar 

  41. Gatzemeier U, Pluzanska A, Szczesna A, et al.: Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol 2004, 22(14S):7010.

    Google Scholar 

  42. Giaccone G, Johnson D, Scagliotti GV, et al.: Results of a multivariate analysis of prognostic factors of overall survival of patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib (ZD1839) in combination with platinum-based chemotherapy (CT) in two large phase III trials (INTACT 1 and 2) [abstract]. Proc ASCO 2003, 22:2522.

    Google Scholar 

  43. Cunningham D, Humblet Y, Siena S, et al.: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004, 351:337–345.

    Article  PubMed  CAS  Google Scholar 

  44. Shepherd FA, Pereira J, Ciuleanu TE, et al.: A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy [abstract]. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial. J Clin Oncol 2004, 22:7022.

    Google Scholar 

  45. Hurwitz H, Fehrenbacher L, Novotny W, et al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350:2335–2342.

    Article  PubMed  CAS  Google Scholar 

  46. Cobleigh MA, Vogel CL, Tripathy D, et al.: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer hat has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999, 17:2639–2648.

    PubMed  CAS  Google Scholar 

  47. Lynch TJ, Bell DW, Sordella R, et al.: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129–2139. This and the article by Paez et al. [48] are excellent examples of important recent developments that help predict a subset of non-small-cell lung cancer patients most likely to benefit from anti-EGFR therapies and point out the importance such work in clinical data interpretation and drug development.

    Article  PubMed  CAS  Google Scholar 

  48. Paez JG, Janne PA, Lee JC, et al.: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497–1500. See annotation for [47].

    Article  PubMed  CAS  Google Scholar 

  49. Guilhot F: Indications for imatinib mesylate therapy and clinical management. Oncologist 2004, 9:271–281.

    Article  PubMed  CAS  Google Scholar 

  50. Gayed I, Vu T, Iyer R, et al.: The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. J Nucl Med 2004, 45:17–21.

    PubMed  CAS  Google Scholar 

  51. Morgan B, Thomas AL, Drevs J, et al.: Dynamic contrastenhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 2003, 21:3955–3964.

    Article  PubMed  CAS  Google Scholar 

  52. Salomon AR, Ficarro SB, Brill LM, et al.: Profiling of tyrosine phosphorylation pathways in human cells using mass spectrometry. Proc Natl Acad Sci U S A 2003, 100:443–448.

    Article  PubMed  CAS  Google Scholar 

  53. Shai R, Shi T, Kremen TJ, et al.: Gene expression profiling identifies molecular subtypes of gliomas. Oncogene 2003, 22:4918–4923.

    Article  PubMed  CAS  Google Scholar 

  54. Schwartz LH, Mazumdar M, Wang L, et al.: Response assessment classification in patients with advanced renal cell carcinoma treated on clinical trials. Cancer 2003, 98:1611–1619.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Section of Hematology/Oncology, Department of Medicine, The University of Chicago, 5841 S. Maryland Avenue, MC 2115, 60637, Chicago, IL, USA

    Apurva A. Desai MD

Authors
  1. Apurva A. Desai MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Walter M. Stadler MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Apurva A. Desai MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Desai, A.A., Stadler, W.M. Novel kinase inhibitors in renal cell carcinoma: Progressive development of static agents. Curr Urol Rep 7, 16–22 (2006). https://doi.org/10.1007/s11934-006-0033-x

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11934-006-0033-x

Keywords

Search

Navigation